For stratification of patients with highly malignant K19+ HCCs and development of clinical applications of K19+ HCC‐CSCs, it is necessary to identify an easily measurable surrogate biomarker of K19+ HCC‐CSCs. The gene discussed is KRT19; the disease is hepatocellular carcinoma.